4.7 Article

Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries

Journal

BRITISH JOURNAL OF PHARMACOLOGY
Volume 167, Issue 8, Pages 1679-1690

Publisher

WILEY
DOI: 10.1111/j.1476-5381.2012.02129.x

Keywords

calcitonin gene-related peptide; calcitonin receptor-like receptor; receptor activity-modifying protein; endothelin-converting enzyme-1; endosome; mesenteric; migraine; smooth muscle cell; vasodilation

Funding

  1. British Heart Foundation [FS/08/017/25027, FS/06/076/21988]
  2. British Heart Foundation [PG/11/93/29143, FS/08/017/25027] Funding Source: researchfish

Ask authors/readers for more resources

Background and Purpose Calcitonin gene-related peptide (CGRP) is a potent vasodilator, implicated in the pathogenesis of migraine. CGRP activates a receptor complex comprising, calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). In vitro studies indicate recycling of CLR?RAMP1 is regulated by degradation of CGRP in early endosomes by endothelin-converting enzyme-1 (ECE-1). However, it is not known if ECE-1 regulates the resensitization of CGRP-induced responses in functional arterial tissue. Experimental Approach CLR, ECE-1a-d and RAMP1 expression in rat mesenteric artery smooth muscle cells (RMA-SMCs) and mesenteric arteries was analysed by RT-PCR and by immunofluorescence and confocal microscopy. CGRP-induced signalling in cells was examined by measuring cAMP production and ERK activation. CGRP-induced relaxation of arteries was measured by isometric wire myography. ECE-1 was inhibited using the specific inhibitor, SM-19712. Key Results RMA-SMCs and arteries contained mRNA for CLR, ECE-1a-d and RAMP1. ECE-1 was present in early endosomes of RMA-SMCs and in the smooth muscle layer of arteries. CGRP induced endothelium-independent relaxation of arteries. ECE-1 inhibition had no effect on initial CGRP-induced responses but reduced cAMP generation in RMA-SMCs and vasodilation in mesenteric arteries responses to subsequent CGRP challenges. Conclusions And Implications ECE-1 regulated the resensitization of responses to CGRP in RMA-SMCs and mesenteric arteries. CGRP-induced relaxation did not involve endothelium-derived pathways. This is the first report of ECE-1 regulating CGRP responses in SMCs and arteries. ECE-1 inhibitors may attenuate an important vasodilatory pathway, implicated in primary headaches and may represent a new therapeutic approach for the treatment of migraine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Cannabidiol improves survival and behavioural co-morbidities of Dravet syndrome in mice

Pabitra Hriday Patra, Eleni Serafeimidou-Pouliou, Michael Bazelot, Benjamin Jason Whalley, Claire Michelle Williams, Alister James McNeish

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Article Clinical Neurology

Pain perception in women with menstrually-related migraine

Katie M. Linstra, Khatera Ibrahimi, Daphne S. van Casteren, Marieke J. H. Wermer, Gisela M. Terwindt, Antoinette MaassenVandenBrink

Summary: This study investigated pain perception in women with menstrually-related migraine throughout different phases of the menstrual cycle. Results showed that women with migraine had lower levels of trigeminal pain compared to healthy controls throughout the cycle, indicating that pain perception varies during the menstrual cycle.

CEPHALALGIA (2021)

Review Pharmacology & Pharmacy

Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid

Cristiana-Ioana Bercea, Graeme S. Cottrell, Francesco Tamagnini, Alister J. McNeish

Summary: Hypertension is characterised by impaired vasodilation, which can be improved by omega-3 polyunsaturated fatty acids such as DHA and EPA. These fatty acids also have vasodilatory effects on vascular smooth muscle cells (VSMCs) by opening potassium channels and possibly voltage-activated potassium channels, leading to hyperpolarisation and relaxation. Structural manipulation of omega-3 PUFAs may lead to novel therapeutic strategies.

BRITISH JOURNAL OF PHARMACOLOGY (2021)

Article Clinical Neurology

Sex differences in prevalence of migraine trigger factors: A cross-sectional study

Daphne S. van Casteren, Iris E. Verhagen, Gerrit L. J. Onderwater, Antoinette MaassenVanDenBrink, Gisela M. Terwindt

Summary: The study showed that females report migraine trigger factors more frequently than males, with menstruation, stress, and bright light being the top triggers for women. Women tend to report more triggers and have a lower migraine threshold compared to men, potentially due to hormonal changes.

CEPHALALGIA (2021)

Review Clinical Neurology

Sex Differences in Response to Triptans A Systematic Review and Meta-analysis

Daphne S. van Casteren, Tobias Kurth, A. H. Jan Danser, Gisela M. Terwindt, Antoinette MaassenVanDenBrink

Summary: Our study found that men had a lower risk for headache recurrence and adverse events in response to triptans, as well as lower drug exposure compared to women. Despite higher drug exposure, women had higher headache recurrence rates possibly due to sex hormonal changes in longer attack duration.

NEUROLOGY (2021)

Article Pharmacology & Pharmacy

Evaluating rimegepant for the treatment of migraine

Tessa de Vries, Linda Al-Hassany, Antoinette MaassenVanDenBrink

Summary: Rimegepant, a small-molecule CGRP receptor antagonist, is well tolerated and effective for acute migraine treatment. However, its therapeutic gain is modest, and the long-term consequences of CGRP blockade require further research.

EXPERT OPINION ON PHARMACOTHERAPY (2021)

Review Geriatrics & Gerontology

Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications

Simone de Vries Lentsch, Eloisa Rubio-Beltran, Antoinette MaassenVanDenBrink

Summary: Migraine is a neurovascular disorder more prevalent in women, driving the urgent need for new preventive medications. Current research targeting CGRP has shown significant effects in clinical trials for prevention and acute treatment of migraine. Further exploration is needed to understand the potential gender-specific differences in CGRP response and potential cardiovascular risks associated with targeting the CGRP pathway in female migraine patients.

MATURITAS (2021)

Article Clinical Neurology

E-diary use in clinical headache practice: A prospective observational study

Daphne S. van Casteren, Iris E. Verhagen, Irene de Boer, Simone de Vries Lentsch, Rolf Fronczek, Erik W. van Zwet, Antoinette MaassenVanDenBrink, Gisela M. Terwindt

Summary: The study showed that the E-diary is useful in diagnosing migraine and can help patients accurately record the number of headache and migraine days, providing reliable information for healthcare providers.

CEPHALALGIA (2021)

Review Clinical Neurology

Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine

Linda Al-Hassany, Antoinette MaassenVanDenBrink

Summary: There have been no reported pharmacokinetic interactions between triptans, ditans, and mAbs targeting CGRP or its receptor. However, there are potential risks, particularly in migraine patients with comorbid cardiovascular disease or with an increased cardiovascular risk profile. More research is needed to better understand the risks and interactions associated with the concurrent use of these drugs.

CURRENT OPINION IN NEUROLOGY (2021)

Review Clinical Neurology

Medication overuse and drug addiction: a narrative review from addiction perspective

Tatiane Teru Takahashi, Raffaele Ornello, Giuseppe Quatrosi, Angelo Torrente, Maria Albanese, Simone Vigneri, Martina Guglielmetti, Cristiano Maria De Marco, Camille Dutordoir, Enrico Colangeli, Matteo Fuccaro, Davide Di Lenola, Valerio Spuntarelli, Laura Pilati, Salvatore Di Marco, Annelies Van Dycke, Ramla Abuukar Abdullahi, Antoinette Maassen van den Brink, Paolo Martelletti

Summary: Chronic headaches are common in migraineurs and can progress to medication overuse headache (MOH). MOH is caused by overuse of painkillers or other medications. While head pain symptoms associated with medication overuse generally improve after stopping regular medication use, behavioral issues such as drug dependence may still persist.

JOURNAL OF HEADACHE AND PAIN (2021)

Article Clinical Neurology

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning, Mikko Karppa

Summary: The efficacy of fremanezumab in reducing migraine and headache days, acute medication use, and disability was demonstrated in patients with difficult-to-treat migraine, regardless of age or sex, according to the FOCUS study.

JOURNAL OF HEADACHE AND PAIN (2021)

Review Cardiac & Cardiovascular Systems

Migraine and cardiovascular disease: what cardiologists should know

Deborah N. Kalkman, Emile G. M. Couturier, Abdelhak El Bouziani, Jorge Dahdal, Jolien Neefs, Janneke Woudstra, Birgit Vogel, Daniela Trabattoni, Antoinette MaassenVanDenBrink, Roxana Mehran, Robbert J. de Winter, Yolande Appelman

Summary: Migraine is a chronic neurovascular disease with complex pathophysiology and multiple causes. Women are more likely to suffer from migraine, and it is the most disabling disease in women under 50 years old. Migraine with aura is associated with increased risk of cardiovascular diseases, such as stroke, atrial fibrillation, myocardial infarction, and cardiovascular death. Medications for migraine treatment may have potential risks for patients with cardiovascular disease. Further research is needed to understand the contraindications for newer treatments. This review discusses the pathophysiology, associations with cardiovascular diseases, current therapies, and future research directions.

EUROPEAN HEART JOURNAL (2023)

Review Clinical Neurology

The 5-HT1F receptor as the target of ditans in migraine - from bench to bedside

Dimos D. Mitsikostas, Christian Waeber, Margarita Sanchez-del-Rio, Bianca Raffaelli, Hakan Ashina, Antoinette Maassen van den Brink, Anna Andreou, Patricia Pozo-Rosich, Alan Rapoport, Messoud Ashina, Michael A. Moskowitz

Summary: Migraine, a leading cause of disability in over one billion people globally, is underestimated even by those who suffer from it. Current treatments have limited efficacy and potential side effects, resulting in low treatment adherence. Recently, a new class of drugs called ditans, selective serotonin 5-HT1F receptor agonists, has been introduced to the international market. This article reviews preclinical studies from the late 1990s and recent clinical research that led to the development and approval of ditans for acute migraine treatment by the US FDA and the European Medicines Agency.

NATURE REVIEWS NEUROLOGY (2023)

Article Physiology

Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease

Dominique M. Bovee, Estrellita Uijl, David Severs, Eloisa Rubio-Beltran, Richard van Veghel, Antoinette Maassen van den Brink, Jaap A. Joles, Robert Zietse, Catherina A. Cuevas, A. H. Jan Danser, Ewout J. Hoorn

Summary: The study using the 5/6 nephrectomy rat model found that spironolactone was effective in reducing hypertension in the high-salt diet group, while targeting aldosterone, the mineralocorticoid receptor, and especially angiotensin II in the normal-salt diet group could lower blood pressure.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)

No Data Available